{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-061288","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.301251+00:00","generated_at":"2026-06-05T01:26:40.003193+00:00","sec_items":["2.02","9.01","7.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Soleno reports Q4 net loss $11.3M; NDA for DCCR in PWS on track for mid-2024","bullets":["Cash and equivalents $169.7M at Dec 31, 2023, boosted by $129M Oct 2023 offering and $43.1M warrant exercises.","R&D expenses rose to $8.7M (Q4 2023) vs $3.8M (Q4 2022); full-year $25.2M vs $15.3M.","Corrected G&A for Q4 2023: $4.1M vs previously reported $4.4M; full-year $13.5M vs $9.8M.","Positive top-line data from C602 withdrawal: primary endpoint met (p=0.0022); DCCR well-tolerated.","Leadership additions: Meredith Manning as CCO, Dairine Dempsey VP Europe, Lauren Budesheim VP HR."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-061288","json":"https://secwatch.observer/filing/0001193125-24-061288.json","markdown":"https://secwatch.observer/filing/0001193125-24-061288.md","text":"https://secwatch.observer/filing/0001193125-24-061288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524061288/0001193125-24-061288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524061288/d764812d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:26:40.003193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c219c5817bc8075313ee8b18c9fe706a61c15b9","claim":"SOLENO THERAPEUTICS INC reported the fourth quarter and year ended December 31, 2023 results: net income Net loss was approximately $11.3 million, or $0.33 per basic and diluted share, for the quarter ended December 31, 2023,, EPS $0.33 per basic and diluted share (Q4 2023); $2.36 per basic and diluted share (FY 2023).","evidence_excerpt":"Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312524061288/0001193125-24-061288-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss was approximately $11.3 million, or $0.33 per basic and diluted share, for the quarter ended December 31, 2023,"},{"label":"EPS","value":"$0.33 per basic and diluted share (Q4 2023); $2.36 per basic and diluted share (FY 2023)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}